The two main forms of intestinal bowel disease, namely ulcerative colitis and Crohn's disease, are not curable but can be controlled by various medical therapies. The Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) has prepared clinical practice guidelines to help physicians prescribe corticosteroids and immunosuppressive drugs for these patients. The guidelines consider therapies that induce remission in patients with active disease as well as treatment regimens that maintain remission. These guidelines complement already existing guidelines from IG-IBD on the use of biological drugs in patients with inflammatory bowel diseases.

Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease : clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease / P. Gionchetti, F. Rizzello, V. Annese, A. Armuzzi, L. Biancone, F. Castiglione, M. Comberlato, M. Cottone, S. Danese, M. Daperno, R. D'Incà, W. Fries, A. Kohn, A. Orlando, C. Papi, M. Vecchi, S. Ardizzone. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 49:6(2017), pp. 604-617.

Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease : clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease

M. Vecchi
Penultimo
;
S. Ardizzone
Ultimo
2017

Abstract

The two main forms of intestinal bowel disease, namely ulcerative colitis and Crohn's disease, are not curable but can be controlled by various medical therapies. The Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) has prepared clinical practice guidelines to help physicians prescribe corticosteroids and immunosuppressive drugs for these patients. The guidelines consider therapies that induce remission in patients with active disease as well as treatment regimens that maintain remission. These guidelines complement already existing guidelines from IG-IBD on the use of biological drugs in patients with inflammatory bowel diseases.
Corticosteroids; Crohn's disease; Guidelines; IBD; Immunosuppressors; Ulcerative colitis; Hepatology; Gastroenterology
Settore MED/12 - Gastroenterologia
2017
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1590865817301871-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.49 MB
Formato Adobe PDF
1.49 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/506004
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 42
social impact